Grufity logo
Grufity logo
ALZN

ALZN - Alzamend Neuro, Inc. Stock Price, Fair Value and News

$1.28+0.05 (+4.07%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

Price Targets

ALZN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALZN Price Action

Last 7 days

12.1%

Last 30 days

27.5%

Last 90 days

-30.1%

Trailing 12 Months

-59.9%

ALZN RSI Chart

ALZN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALZN Valuation

Market Cap

4.5M

Price/Earnings (Trailing)

-0.77

EV/EBITDA

-0.02

Price/Free Cashflow

-0.57

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALZN Fundamentals

ALZN Revenue

ALZN Earnings

Earnings (TTM)

-5.9M

Earnings Growth (Yr)

26.5%

Earnings Growth (Qtr)

62.97%

ALZN Profitability

Return on Equity

-134.48%

Return on Assets

-115.53%

Free Cashflow Yield

-174.08%

ALZN Investor Care

Shares Dilution (1Y)

1487.86%

Diluted EPS (TTM)

-1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025----
2024----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Alzamend Neuro, Inc.

ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
 CEO
 WEBSITEalzamend.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES4

Alzamend Neuro, Inc. Frequently Asked Questions

ALZN is the stock ticker symbol of Alzamend Neuro, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of Alzamend Neuro, Inc. is 4.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.